Navigation Links
King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
Date:6/25/2009

ACUROX(R) and EMBEDA (TM) Data Highlighted at the College on Problems of Drug Dependence Annual Meeting

RENO, Nev., June 25 /PRNewswire/ -- King Pharmaceuticals, Inc. (NYSE: KG) today announced that the Company is presenting safety and efficacy data for ACUROX(R) and EMBEDA(TM) (ALO-01), two novel opioid analgesic formulations that are in development, at the 71st Annual Meeting of the College on Problems of Drug Dependence. King is also developing other pain medicines employing unique technology platforms designed to address risks associated with currently marketed opioids.

"We anticipate that ACUROX(R) and EMBEDA(TM), upon approval, will offer new therapeutic tools for physicians treating people living with pain," said Eric Carter, Chief Science Officer of King Pharmaceuticals. "Our expectation is that these novel technologies could become instrumental in a physician's arsenal of safe and effective pain medicines that can help with an overall risk management plan."

Highlights of King's presentations and King supported presentations are as follows:

ACUROX(R) (oxycodone HCl/niacin) Tablets for the Treatment of Acute, Moderate to Severe Pain Following Bunionectomy Surgery in Adult Patients

ACUROX(R) Tablets are a unique composition of short-acting oxycodone HCl, niacin and functional inactive ingredients intended to relieve moderate to severe pain. A Phase III study evaluated the analgesic efficacy and safety of ACUROX(R) in adults with moderate to severe pain following bunionectomy surgery. The 405 participants received either two ACUROX(R) Tablets 7.5/30 mg, two ACUROX(R) Tablets 5/30 mg or two placebo tablets every six hours for 48 hours after surgery. Both doses of ACUROX(R) Tablets demonstrated significant reduction in pain compared to placebo. The adv
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014  Wearable sports and activity ... less than two years, producing a massive amount ... huge opportunity exists for leveraging this data to ... ) introduced a first-of-its-kind wearable analytics platform for ... of clinical research linking activity and health risks, ...
(Date:9/16/2014)... Sept. 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), ... of chronic pain, announced today that it has entered ... (MSKCC) in a series of animal studies for levorphanol, ... extended release form of levorphanol.  Gavril Pasternak, MD, PhD, ... Dr. Pasternak said, "Levorphanol is a ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Henry Schein To Present At The Leerink Partners Services Roundtable 2
(Date:9/16/2014)... September 16, 2014 Recently, BuyTopDress.com, one ... has unveiled its new collection of elegant graduation ... these brand new items are on sale on the ... from 23 to 63 percent off. , These ... and design. They are available in a lot of ...
(Date:9/16/2014)... CA (PRWEB) September 16, 2014 Dr. ... the launch of ACLsurgeryLA.com , a specialty website ... injuries. As an avid sports lover and athlete, ... for treatment and recovery from injuries to maintain active, ... to offer patients a resource dedicated specifically to ...
(Date:9/16/2014)... 2014 MEDICC Review today ... genetics in Cuba. Although the articles do not ... are intrinsically connected, since cancers begin with errors in ... full spectrum of cancer control, from primary prevention to ... topic of an exclusive interview with National Medical ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Lambda Solutions, a ... systems , is excited to welcome Stewart Rogers ... Harvey, Sales Executive at Lambda Solutions comments, “Product leadership will ... right candidate to do so. Learning and talent management is ... changes to help clinical learning and talent development in the ...
(Date:9/16/2014)... Birmingham, Alabama (PRWEB) September 16, 2014 *To ... Birmingham, AL, visit Achieve Clinical Research on the web ( ... For those who qualify:, There is ... required , Compensation may be provided for ... stands, pneumonia and influenza are the eighth leading cause of ...
Breaking Medicine News(10 mins):Health News:Cheap Graduation Dresses Now Provided Online At BuyTopDress.com 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 2Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 3Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 2Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 3Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3
... Sciton Inc., a manufacturer,of laser and ... announced the introduction of an additional fractional,device, ... features,-- significantly higher speed, and user-controlled, variable-depth ... results and excellent practice,economics., Up to ...
... Babies born,preterm were more than twice as likely ... a new analysis of nearly 7 million U.S.,live births ... and,Child Health Journal., Preterm birth, live birth before ... according to the March of Dimes. More than,a half ...
... that the frequency with which critically-ill patients developed,ventilator-associated ... medical center such as Mayo Clinic compared to ... National Healthcare Safety,Network (NHSN). This is good news ... generally strong across the U.S. in intensive care ...
... Dots beads led to a voluntary recall of the product ... that the potentially toxic chemical 1,4-butanediol (BD) had been used ... in the manufacture of the beads. , A new study, ... Irvine confirms these reports, finding that Aqua Dots contained no ...
... Inc. (OTC,Bulletin Board: SYMD) announced today that its Board ... The shareholder rights plan is,designed to ensure that shareholders ... an attempted takeover of the company and to protect ... plan,was not approved for adoption as a result of ...
... But, it may not be for every patient, one expert ... advanced prostate cancer that hasn,t spread beyond the gland should ... removed, a new long-term study says. , "What we are ... men who were treated with radiation and those who weren,t," ...
Cached Medicine News:Health News:Sciton Introduces ProFractional-XC(TM), High-Speed, Dual-Mode Fractional Laser 2Health News:Analysis of Millions of U.S. Births Shows Association Between Birth Defects and Preterm Birth 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 3Health News:Study finds that recalled Aqua Dots did contain poisonous chemical 2Health News:SyntheMed, Inc. Adopts Shareholder Rights Plan 2Health News:Radiation Improves Survival for Advanced Prostate Cancer 2Health News:Radiation Improves Survival for Advanced Prostate Cancer 3
The ADx system uses fluorescence polarization immunoassay technology for the detection of abused drugs and toxicology assays....
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry....
... The Access immunoassay system ... access benchtop analyzer that ... assays, with panels that ... thyroid, infectious disease, blood ...
...
Medicine Products: